Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278.
Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, Keavney B, Collins R, Wiman B, de Faire U and Danesh J (2007) Association of apolipoprotein E genotypes with lipid levels and coronary risk. Jama 298: 1300-1311.
Carr DF, O'Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G, van Staa T and Pirmohamed M (2013) SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther 94: 695-701.
Dendramis G (2011) Interindividual differences in the response to statin therapy and gene polymorphisms related to myopathy during statin therapy. G Ital Cardiol (Rome) 12: 182-185.
Feng Q, Wilke RA and Baye TM (2012) Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics 13: 579-594.
Giannakopoulou E, Ragia G, Kolovou V, Tavridou A, Tselepis AD, Elisaf M, Kolovou G and Manolopoulos VG (2014) No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. Mol Biol Rep 41: 4631-4638.
Griffin BA, Walker CG, Jebb SA, Moore C, Frost GS, Goff L, Sanders TAB, Lewis F, Griffin M, Gitau R, Lovegrove JA (2018) APOE4 Genotype Exerts Greater Benefit in Lowering Plasma Cholesterol and Apolipoprotein B than Wild Type (E3/E3), after Replacement of Dietary Saturated Fats with Low Glycaemic Index Carbohydrates. Nutrients 10.
Hamilton-Craig I (2001) Statin-associated myopathy. Medical Journal of Australia 175: 486-489.
Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS (2008) Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 155: 772-779.
Hubáček JA, Dlouhá D, Adámková V, Zlatohlavek L, Viklický O, Hrubá P, Češka R, Vrablík M (2015) SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med Sci Monit 21: 1454-1459.
Jiang F, Choi JY, Lee JH, Ryu S, Park ZW, Lee JG, Na HS, Lee SY, Oh WY, Chung MW, Choi SE (2017) The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition. Pharmacogenomics 18: 459-469.
Jiang J, Tang Q, Feng J, Dai R, Wang Y, Yang Y, Tang X, Deng C, Zeng H, Zhao Y, Zhang F (2016) Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis. Springerplus 5: 1368.
Kaewboonlert N, Thitisopee W, Sirintronsopon W, Porntadavity S and Jeenduang N (2018) Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients. J Clin Pharm Ther 43: 647-655.
Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M and Chiba K (2005) Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics 15: 513-522.
Li, SM (2014) Population migration regional economic growth and income determination: a comparative study of Dongguan and Meizhou China. Urban Studies 34: 999-1026.
Liang S, Pan M, Geng HH, Chen H, Gu LQ, Qin XT, Qian JJ, Zhu JH, Liu CF 2009 Apolipoprotein E polymorphism in normal Han Chinese population: frequency and effect on lipid parameters. Mol Biol Rep 36: 1251-1256.
SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M and Collins R (2008) SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 359: 789-799.
Mahley RW and Rall SC Jr (2000) Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1: 507-537.
Marais AD (2019) Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology 51: 165-176.
Melo MS, Balanco L, Branco CC and Mota-Vieira L (2015) Genetic variation in key genes associated with statin therapy in the Azores Islands (Portugal) healthy population. Ann Hum Biol 42: 283-289.
Meyer zu Schwabedissen HE, Albers M, Baumeister SE, Rimmbach C, Nauck M, Wallaschofski H, Siegmund W, Völzke H, Kroemer HK (2015) Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort. Pharmacogenet Genomics 25: 8-18.
Miller BR and Kung Y (2018) Structural Features and Domain Movements Controlling Substrate Binding and Cofactor Specificity in Class II HMG-CoA Reductase. Biochemistry 57: 654-662.
Mladenovska K, Grapci AD, Vavlukis M, Kapedanovska A, Eftimov A, Geshkovska NM, Nebija D, Dimovski AJ (2017) Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in Macedonian subjects. Pharmazie 72: 288-295.
Nies AT, Niemi M, Burk O, Winter S, Zanger UM, Stieger B, Schwab M, Schaeffeler E (2013) Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med 5: 1.
Nozawa T, Minami H, Sugiura S, Tsuji A and Tamai I (2005) Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33: 434-439.
Ramakumari N, Indumathi B, Katkam SK and Kutala VK (2018) Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J 70 Suppl 3: S120-s125.
Rocha KCE, Pereira BMV and Rodrigues AC (2018) An update on efflux and uptake transporters as determinants of statin response. Expert Opin Drug Metab Toxicol 14: 613-624.
Tang H, Yan X, Hua Y, Wei M, Zhang L, Gao J, Dong H (2005) Distribution of apoE polymorphism in Chinese Yunnan Dehong Dai ethnic group. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22: 224-226.
Tirona RG, Leake BF, Wolkoff AW and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304: 223-228.
Treenert A, Areepium N and Tanasanvimon S (2018) Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy. Asian Pac J Cancer Prev 19: 2757-2764.
Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS (2009) The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 54: 1609-1616.
Wanmasae S, Sirintronsopon W, Porntadavity S and Jeenduang N (2017) The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients. Cardiovasc Ther 35.
Wu X, Gong C, Weinstock J, Cheng J, Hu S, Venners SA, Hsu YH, Wu S, Zha X, Jiang S, Li Y, Pan F, Xu X (2018) Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia. Clin Appl Thromb Hemost, 1076029618805863.
Yang JD, Feng GY, Zhang J, Cheung J, St Clair D, He L, Ichimura K (2003) Apolipoprotein E -491 promoter polymorphism is an independent risk factor for Alzheimer's disease in the Chinese population. Neurosci Lett 350: 25-28.
Zhong Z, Wu H, Li B, Li C, Liu Z, Yang M, Zhang Q, Zhong W, Zhao P (2018) Analysis of SLCO1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China. J Clin Lab Anal.
Zhou J, Xue YL, Guan YX, Yang YD, Fu SB, Zhang JC (2005) Association study of apolipoprotein e gene polymorphism and cerebral infarction in type 2 diabetic patients. Yi Chuan 27: 35-38.
Zintzaras E, Kitsios GD, Triposkiadis F, Lau J and Raman G (2009) APOE gene polymorphisms and response to statin therapy. Pharmacogenomics J 9: 248-257.